October 11, 2018 — Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and ...
Ashish Pershad, M.D., medical director, structural heart program, Banner University Medical Heart Institute, Phoenix ...
September 7, 2018 — The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival ...
September 7, 2018 — A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s ...
September 6, 2018 — Tafamidis is the first treatment to improve survival and reduce hospitalizations in a rare heart ...
September 5, 2018 — Aspirin prevented serious vascular events in patients with diabetes who did not already have ...
September 4, 2018 — The jury is still out on whether people at moderate risk of a first heart attack or stroke should ...
August 31, 2018 — Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge ...
August 27, 2018 — Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertensi ...
June 29, 2018 — Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with Xar ...
June 27, 2018 — Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce ...
June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients ...
June 7, 2018 — Results from an international clinical trial show that combining clopidogrel and aspirin following a ...
May 30, 2018 — Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at ...